Skip to main content
An official website of the United States government

Mirvetuximab Soravtansine for the Treatment of Folate Receptor-Alpha Positive Persistent or Recurrent Endometrial Cancer

Trial Status: active

This phase II trial studies the effect of mirvetuximab soravtansine in treating patients with folate receptor-alpha positive endometrial cancer that remains despite treatment (persistent) or has come back (recurrent). Mirvetuximab soravtansine is a monoclonal antibody, called mirvetuximab, linked to a chemotherapy drug, called soravtansine. Mirvetuximab is a form of targeted therapy because it attaches to specific receptors on the surface of cancer cells, known as folate receptor-alpha receptors, and delivers soravtansine to kill them.